SCHEMBL4137879

SCHEMBL4137879

Cc1cccc(-c2ccc3nc(Cl)nc(N4CCOCC4)c3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.54
LMNA P02545 7/20 0.50
ALDH1A1 P00352 6/20 0.50
MAPK1 P28482 5/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
HIF1A Q16665 4/20 0.50
CLK4 Q9HAZ1 4/20 0.50
TSHR P16473 3/20 0.50
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 3/20 0.50
PIK3CA P42336 2/20 0.50
CYP2C19 P33261 2/20 0.50
USP2 O75604 2/20 0.50
CYP2D6 P10635 1/20 0.50
MTOR P42345 1/20 0.50
EGLN1 Q9GZT9 1/20 0.48
KDM4E B2RXH2 4/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4792397 0.89 SMN1; SMN2 (0.57) SMN1; SMN2LMNAALDH1A1MAPK1MEN1
SCHEMBL14412719 0.86 PIK3CA (0.55) LMNAALDH1A1MAPK1MEN1KMT2A
SCHEMBL4879139 0.83 ALDH1A1 (0.69) SMN1; SMN2LMNAALDH1A1MAPK1MEN1
SCHEMBL4121396 0.81 CLK4 (0.73) SMN1; SMN2LMNAALDH1A1MAPK1MEN1
SCHEMBL427063 0.80 LMNA (0.49) LMNAALDH1A1MAPK1MEN1KMT2A
SCHEMBL423639 0.79 HIF1A (0.51) LMNAALDH1A1MAPK1MEN1KMT2A
SCHEMBL3718191 0.79 SMN1; SMN2 (0.62) SMN1; SMN2LMNAALDH1A1MAPK1MEN1
SCHEMBL3776763 0.79 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL426124 0.78 ALDH1A1 (0.48) LMNAALDH1A1MAPK1MEN1KMT2A
SCHEMBL428110 0.78 LMNA (0.47) LMNAALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318730-B2 Fused hetrocyclic compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-11-27 US disclosed
US-7615552-B2 Fused heterocyclic compounds SYNTA PHARMACEUTICALS CORP. (US) 2009-11-10 US disclosed
US-20090253694-A1 Fused hetrocyclic compounds SYNTA PHARMACEUTICALS CORP. (US) 2009-10-08 US disclosed
US-20050250770-A1 Fused heterocyclic compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250770-A1 Fused heterocyclic compounds IL2, IL4, IL15 SMN1; SMN2 1865/4885LMNA 1697/4885ALDH1A1 842/4885
US-20090253694-A1 Fused hetrocyclic compounds IL2, IL15, IL4 SMN1; SMN2 2900/4885LMNA 1387/4885ALDH1A1 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.